Efficacy and safety of ephedra-containing oral medications: a systematic review, meta-analysis, and exploratory dose-response analysis for weight reduction.

IF 4.4 2区医学 Q1 PHARMACOLOGY & PHARMACY

Frontiers in Pharmacology Pub Date : 2024-10-30 eCollection Date: 2024-01-01 DOI:10.3389/fphar.2024.1397247

Hyeongyu Cho, Jeewoo Oh, Hongmin Chu, Hanbit Jin, Jungtae Leem

{"title":"Efficacy and safety of ephedra-containing oral medications: a systematic review, meta-analysis, and exploratory dose-response analysis for weight reduction.","authors":"Hyeongyu Cho, Jeewoo Oh, Hongmin Chu, Hanbit Jin, Jungtae Leem","doi":"10.3389/fphar.2024.1397247","DOIUrl":null,"url":null,"abstract":"Introduction: Despite the widespread use of ephedra in various forms, including food supplements and herbal prescriptions, comprehensive studies reviewing its efficacy and safety across different countries are lacking.Methods: We systematically searched 5 electronic databases and conducted a meta-analysis of 16 randomized controlled trials (RCTs) on ephedra-containing oral medications (EOMs), performing a dose-response analysis for weight loss.Results: The meta-analysis results revealed a statistically significant reduction in the body mass index (BMI) (MD: 1.5 kg/m2; 95% CI: -2.46 to -0.54) and secondary outcomes like body weight (BW) and waist circumference (WC). The dose-response analysis indicated a correlation between ephedra and weight reduction. The safety analysis showed no significant difference in adverse effects between the treatment and control groups (RR = 0.99, 95% CI = 0.80 ∼ 1.21, and p = 0.90).Discussion: In conclusion, EOMs demonstrated effectiveness in promoting weight loss, and the dose-response analysis indicated a correlation between ephedra and weight reduction. However, additional research is necessary due to the limited number of studies and inconsistent results among the assessment criteria. Moreover, if prescribed by traditional medicine physicians within the permissible daily ephedrine dosage range of 150 mg set by the Food and Drug Administration (FDA) and monitored by healthcare professionals, the risk of severe adverse events is likely to be minimal.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=387895, identifier CRD42023387895.","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1397247"},"PeriodicalIF":4.4000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557485/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1397247","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Despite the widespread use of ephedra in various forms, including food supplements and herbal prescriptions, comprehensive studies reviewing its efficacy and safety across different countries are lacking.

Methods: We systematically searched 5 electronic databases and conducted a meta-analysis of 16 randomized controlled trials (RCTs) on ephedra-containing oral medications (EOMs), performing a dose-response analysis for weight loss.

Results: The meta-analysis results revealed a statistically significant reduction in the body mass index (BMI) (MD: 1.5 kg/m2; 95% CI: -2.46 to -0.54) and secondary outcomes like body weight (BW) and waist circumference (WC). The dose-response analysis indicated a correlation between ephedra and weight reduction. The safety analysis showed no significant difference in adverse effects between the treatment and control groups (RR = 0.99, 95% CI = 0.80 ∼ 1.21, and p = 0.90).

Discussion: In conclusion, EOMs demonstrated effectiveness in promoting weight loss, and the dose-response analysis indicated a correlation between ephedra and weight reduction. However, additional research is necessary due to the limited number of studies and inconsistent results among the assessment criteria. Moreover, if prescribed by traditional medicine physicians within the permissible daily ephedrine dosage range of 150 mg set by the Food and Drug Administration (FDA) and monitored by healthcare professionals, the risk of severe adverse events is likely to be minimal.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=387895, identifier CRD42023387895.

查看原文本刊更多论文

含麻黄成分口服药物的疗效和安全性：系统综述、荟萃分析和对减轻体重的探索性剂量反应分析。

简介：尽管麻黄以各种形式被广泛使用，包括食品补充剂和草药处方，但在不同国家缺乏对其疗效和安全性的全面研究：我们系统地检索了 5 个电子数据库，并对 16 项关于含麻黄成分口服药物（EOMs）的随机对照试验（RCTs）进行了荟萃分析，对减肥效果进行了剂量-反应分析：荟萃分析结果显示，体重指数（BMI）（MD：1.5 kg/m2；95% CI：-2.46 至 -0.54）以及体重（BW）和腰围（WC）等次要结果均有统计学意义的显著降低。剂量反应分析表明，麻黄与体重下降之间存在相关性。安全性分析表明，治疗组和对照组的不良反应无明显差异（RR = 0.99，95% CI = 0.80 ∼ 1.21，P = 0.90）：总之，EOMs 具有促进减肥的功效，剂量反应分析表明麻黄与体重减轻之间存在相关性。然而，由于研究数量有限且评估标准结果不一致，因此有必要开展更多研究。此外，如果传统医学医生在美国食品药品管理局（FDA）规定的每日麻黄碱允许剂量范围（150 毫克）内开具处方，并由医护人员进行监控，发生严重不良事件的风险可能微乎其微。系统综述注册：https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=387895，标识符为 CRD42023387895。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.80

自引率

8.90%

发文量

5163

审稿时长

14 weeks

期刊介绍： Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.